Innovation in sepsis trials: rethinking endpoints, statistics and patient stratification

Area of Science:

• Critical care medicine
• Translational research
• Clinical trial design

Background:

• Effective causal therapies for sepsis are lacking, with a significant gap between research and clinical application.
• Traditional randomized clinical trials (RCTs) for sepsis have often failed due to patient heterogeneity, complex immune responses, and broad outcome measures.

Purpose of the Study:

• To explore how precision medicine approaches and novel trial designs can overcome limitations in traditional sepsis research.
• To highlight recent studies demonstrating improved outcomes through patient stratification and biologically informed endpoints.

Main Methods:

• Review of recent sepsis trials (ANDROMEDA-SHOCK-2, IMMUNOSEP, INSPIRE, TIGRIS) employing precision medicine strategies.
• Analysis of patient stratification based on physiological or immunological phenotypes.
• Examination of novel endpoints and adaptive statistical frameworks.

Main Results:

• ANDROMEDA-SHOCK-2 utilized capillary refill time and a win-ratio endpoint for personalized resuscitation.
• IMMUNOSEP stratified patients by immune status, showing improved organ function (SOFA score) with targeted therapy.
• Other trials (INSPIRE, TIGRIS) used specific patient enrichment and advanced statistical methods to increase trial efficiency and sensitivity to treatment effects.

Conclusions:

• Aligning interventions with biological pathways, using adaptive designs, and employing biologically informed endpoints can reveal benefits missed by conventional trials.
• A conceptual shift towards precision-guided therapies, adaptive protocols, and biologically relevant endpoints is emerging in sepsis research.
• These advancements suggest a move away from universal treatment failures towards more targeted and effective critical care interventions for sepsis.